Ghrelin, the only known circulating appetite stimulant, has garnered widespread scientific interest and is currently featured in more than 2.3 new publications per day. Antagonists and agonists of its receptor are vigorously being developed by pharmaceutical companies to treat obesity and wasting conditions respectively. Here, the authors summarize the current state of knowledge regarding ghrelin's roles in energy homeostasis.
Introduction
The discovery of ghrelin in December 1999 marked the culmination of longstanding efforts to ''deorphanize'' the GH secretagogue receptor (GHS-R), which mediates the effects of synthetic GH secretagogues [1] . Ghrelin stimulates GH secretion in humans and other animals even more effectively than does GH releasing hormone. The identification of ghrelin as a long-sought endogenous ligand for GHS-R seemed, at first, to be a watershed event limited to the field of GH research. Indeed, the initial modest pace of publications on this new hormone -a dozen in the first year -reflected its apparent position as a novel player in a subspecialty field. Toward the end of that year, however, it was reported that ghrelin potently increases food intake and body weight [2-4], a discovery that catapulted the hormone into the scientific and popular limelight. Now, 4 years later, there are over 1000 publications on ghrelin, and news of its orexigenic effects has been broadcast extensively throughout the media. GHS-R is expressed widely in peripheral and central tissues and, accordingly, ghrelin can exert diverse biologic actions, including effects on hormone secretion, glucose homeostasis, pancreatic function, gastrointestinal motility, cardiovascular function, immunity, inflammation, cell proliferation and survival, bone metabolism, reproduction, sleep, and more [5 •• ]. Although ghrelin's pharmacologic impact on GH secretion remains of great interest, considerable evidence challenges whether this action is physiologically important.
The current review focuses on ghrelin's most famous attribute, as the only known circulating orexigen, or appetite stimulant. We present evidence that favors roles for ghrelin in the short-term regulation of pre-meal hunger and meal initiation, as a unique orexigenic counterpart to meal-related satiety factors, such as CCK. We also highlight data demonstrating that ghrelin satisfies established criteria to be viewed as a participant in long-term body weight regulation -a potential orexigenic counterpart to leptin and insulin in this regard.
Biochemistry and tissue distribution of ghrelin
Ghrelin is a 28-amino acid peptide cleaved from a larger precursor, preproghrelin, which bears a signal sequence dictating secretion into blood [1] . The peptide undergoes a posttranslational modification in which the serine-3 residue is covalently linked to a medium-chain fatty acid, typically octanoic acid, through an ester bond. This type of acylation is entirely unique to ghrelin and is required for the peptide to bind to its classical receptor, GHS-R1a. Consequently, most biologic actions of ghrelin, especially those involving endocrine and anabolic effects, require acylated ghrelin [5 •• ]. The observation that octanoylation is unique to ghrelin and is required for most of its effects has potential therapeutic implications, should blockade of ghrelin signaling prove clinically useful. Antagonists to the putative, undiscovered transacylation enzyme that octanoylates ghrelin would inactivate the hormone in a highly selective manner.
The ratio of acylated to des-acyl forms is approximately the same in tissues that synthesize ghrelin (e.g., stomach and pituitary) as it is in blood [6, 7] , suggesting that acylation occurs in the cells of origin. A small but growing body of literature claims roles for des-acyl ghrelin in adipogenesis [ It is tempting to speculate that des-acyl ghrelin has physiologic functions, given that its concentrations in tissues and blood are nearly 10 times those of acylated ghrelin, and we would like to think that nature is too frugal to synthesize a functionless peptide. Most of the data suggesting actions of des-acyl ghrelin, however, come from pharmacologic or in-vitro studies, and these observations may reflect effects of supraphysiologic doses of des-acyl ghrelin cross-reacting with heterologous receptors. Pending the discovery of a specific receptor for des-acyl ghrelin, claims of physiologic roles for this entity remain conjectural.
Recent experiments in mice lacking the GHS-R gene proved definitively that the orexigenic and GH stimulatory effects of acylated ghrelin are mediated by this receptor [17 •• ,18 • ]. Thus, the 'GHS-R' can now be properly renamed 'ghrelin receptor.' This seven-membrane-spanning receptor couples to both Gq/phospholipase C and Gs/protein kinase A pathways, and it exhibits an unusual feature of significant ligand-independent constitutive activity [19 • ,20 • ]. These features have important implications for pharmaceutical companies developing ghrelin receptor blockers. The most effective compounds may be inverse agonists, rather than neutral competitive antagonists, and they may need to inhibit more than one type of intracellular signaling pathway.
The receptor-binding pharmacophore of acylated ghrelin appears to consist of approximately the first seven or fewer amino acids at the N-terminus plus the fatty acid moiety, because full receptor binding and activation are achieved with only these residues [21] . Except for very conservative serine-to-threonine substitutions in goldfish and bullfrogs, the sequence of these seven amino acids is universally conserved among 32 species studied to date, including mammals, birds, amphibians, reptiles, and fish. Such faithful conservation, which is greater than that of leptin, for example, suggests that ghrelin subserves primordial and important biologic roles.
The stomach is the principal site of ghrelin synthesis, producing approximately 10 times more of the hormone per gram of tissue than the next richest source: the duodenum [1,6, 22, 23] . Lesser concentrations are present throughout the small intestine, generally diminishing with increasing distance from the pylorus [22] [23] [24] . The impact of gastrectomy or extensive small bowel resection on plasma ghrelin levels suggests that at least two-thirds of circulating ghrelin is secreted by the stomach, and roughly the remaining one-third arises from the small intestine [22, 25] . Within the stomach, ghrelin is produced by enteroendocrine cells in the oxyntic mucosa that were previously dubbed ''X/A-like cells,'' but should now be renamed ''ghrelin cells'' [6] . Most of these are ''closed,'' meaning that they appose the basolateral membrane adjacent to the bloodstream but do not directly contact the gastric lumen [6, 24] . More distally in the intestine, ghrelin cells become increasingly ''open,'' contacting both the intestinal lumen and blood vessels [24] . Minor amounts of ghrelin are produced in diverse additional tissues, often detectable only by reverse transcription-polymerase chain reaction (RT-PCR) [23] . These sites include the lungs, pancreatic islets, gonads, adrenal cortex, placenta, kidney, and more. Autocrine, paracrine, or neurocrine effects of ghrelin in these tissues may mediate some of the protean actions that the peptide is hypothesized to exert based on pharmacologic and in-vitro experiments [5 •• ]. Fascinating genetic studies into pancreatic islet cell development have recently identified a novel, ghrelin-producing islet cell type, the e cell [26 •• ]. Derived from the same progenitors as the four classic islet cell types, e cells replace these other islet cells when the latter are eliminated by genetic deletion of vital transcription factors. Ghrelin is highly expressed in the fetal pancreas, where it may participate in islet cell development, and preliminary evidence suggests a paracrine effect on insulin secretion in adults.
Importantly, minute amounts of ghrelin are claimed to be synthesized in the hypothalamus, adjacent to key neurons regulating energy balance. A large group of distinguished investigators reported that ghrelin-containing neurons, with cell bodies positioned between the classic hypothalamic nuclei, synapse with neurons that cosecrete the well-known orexigens, neuropeptide Y (NPY) and agoutirelated protein (Agrp), as well as with other neurons involved in energy homeostasis [27 •• ] . Despite these findings, the existence of centrally produced ghrelin remains controversial. Although ghrelin immunoreactivity can be detected in the hypothalamus [1,27 •• ], this finding does not prove that ghrelin is produced centrally, because the peptide might gain access to the central nervous system (CNS) from the circulation, across an incomplete blood-brain barrier in this region. Many groups (including our own) have attempted, but failed, to detect ghrelin mRNA in the CNS by in-situ hybridization. In the publication mentioned above [27 •• ], ghrelin mRNA was detected in the CNS by the more sensitive method of RT-PCR. Quite a few groups (including our own), however, have been unable to demonstrate ghrelin in the CNS even using this technique. Similarly, among knockout mice in which the ghrelin gene is replaced by a lacZ reporter gene, researchers have generally not detected hypothalamic b-galactosidase staining, which would indicate transcription driven by the ghrelin promoter in that location, although some signal can be detected by PCR [28 • ,29 • ]. In our opinion, ghrelin probably is synthesized within the brain, but in extremely small quantities, and the physiologic significance of this source remains to be established. Critical experiments to address this question, such as the generation of neuron-specific ghrelin knockout mice, will be very challenging because of the modest phenotype of global ghrelin-deficient animals (vide infra).
Roles for ghrelin in meal initiation
Although mealtime hunger is a common, daily experience, the molecular determinants of this sensation remain enigmatic after decades of research to identify them. The following observations from rodent studies suggest that ghrelin contributes to preprandial hunger and participates in meal initiation: 
The primary effect of ghrelin injections on meal pat-
terns is to decrease the latency to feed, leading to one extra bout of feeding immediately after ghrelin administration [31 • ]. 5. Ghrelin stimulates gastric motility and acid secretion, both of which increase in anticipation of meals [30, 32] . 6. The most clearly documented targets of ghrelin action in the brain -hypothalamic NPY/Agrp neurons [33 • ]are implicated in the central control of meal initiation, because levels of these neuropeptides increase at times of maximal spontaneous feeding in rodents [34] . In contrast, the expression of other neuropeptides involved in energy balance is relatively constant throughout the day.
The hypothesis that endogenous ghrelin is a physiologic meal initiator predicts that circulating levels should increase before, and decrease after, every meal, and that peak concentrations should be sufficiently high to 
Roles for ghrelin in body weight regulation
Body weight is regulated by the process of energy homeostasis, whereby total energy intake and expenditure are closely matched over long periods of time [50 • ]. Deviations from a genetically influenced level of defended body weight engage adaptive, centrally mediated alterations in appetite and energy expenditure that resist weight change, rendering nonsurgical weight loss interventions relatively ineffective. Implicit in this regulatory feedback loop is the existence of ''adiposity signals'' that communicate the status of energy stores in the body to the brain. Leptin and insulin are accepted as adiposity hormones because they fulfill a series of criteria that should be met by any such agent [51] . In this section we present evidence that ghrelin also satisfies these criteria and may thus be a unique anabolic counterpart to leptin and insulin. The criteria are as follows.
1. An adiposity hormone should circulate in proportion to body energy stores and manifest compensatory changes in response to fluctuations in these stores
If circulating ghrelin acts as a barometer of energy stores, its levels should correlate with adipose tissue mass. Indeed, ghrelin levels correlate inversely with numerous measures of adiposity across a very wide body weight range, converse to the relation between adiposity and leptin or insulin levels [22, 35, [52] [53] [54] [55] [56] . In addition, ghrelin levels should show compensatory changes to alterations in body weight -specifically, increasing with weight loss and decreasing with weight gain [33 • ]. Indeed, such alterations in ghrelin levels have been reported in the context of various conditions of body weight change. Ghrelin levels increase in response to weight loss resulting from low-calorie diets [39, 57] , mixed lifestyle modifications [58] , cancer anorexia [57, 59] , Huntington disease [60] , anorexia nervosa [22, 35, 55] , and chronic failure of the heart [61] , lungs [62] , liver [63] , or kidneys [64] . Conversely, we and our colleagues find that ghrelin levels decrease with weight gain resulting from forced overfeeding (Williams DL, Grill HJ, Cummings DE, Kaplan JM, unpublished data). Similar changes occur with glucocorticoid-induced weight gain [65] . Together, these observations suggest that ghrelin levels respond in a compensatory fashion to bidirectional alterations in body weight, consistent with the hypothesis that ghrelin contributes to the known adaptive metabolic responses to such alterations [50 • ].
As a result of the fact that all the conditions of weight loss cited above are characterized by low food intake, it is theoretically possible that the associated high ghrelin levels arise from decreased inhibitory input by ingested nutrients, rather than from weight loss per se. We have found, however, that weight loss achieved through a 1-year aerobic exercise program also triggers an increase in human plasma ghrelin levels, in the absence of changes in caloric intake [65a] . Conversely, we found that mice subjected to mild caloric restriction, insufficient to cause weight loss (presumably because of compensatory changes in energy expenditure), manifested no change in ghrelin levels (Bush et al. Paper presented at the 85th annual meeting of the Endocrine Society, Philadelphia, PA, 2003). These observations suggest that ghrelin levels respond to changes in body weight -not simply to enteric nutrient load. Although it is not yet clear how ghrelin-producing cells in the gut sense changes in energy stores, extant evidence suggests that they respond, at least in part, to adiposityassociated fluctuations in levels of insulin [66, 67] , but not leptin [68 • ].
If an increase in ghrelin levels constitutes one of the physiologic adaptations that resists weight loss, it is important to examine the response of ghrelin to weight loss achieved by traditionally successful means. Low-fat diets are the most well documented dietary means to lose weight [69] , and interestingly, weight loss achieved by this method fails to elicit a compensatory increase in 24-hour plasma ghrelin profiles [40 • ]. Similarly, the most effective, approved method for major, sustained weight loss -gastric bypass surgery -typically suppresses or at least constrains ghrelin levels, possibly contributing to the appetite reduction and durable success of this procedure [39, 70] . Ghrelin suppression is not universally observed after gastric bypass, however, perhaps due to differences in surgical technique, such as treatment of autonomic innervation to the foregut [49 • ,71 • ]. A compelling priority in current research is to prove whether compromised ghrelin production contributes to the efficacy of gastric bypass surgery and, if so, to clarify the underlying mechanisms, so that this effect can be purposefully achieved.
2. An adiposity hormone should influence neuronal activity in brain centers known to regulate body weight Although humoral ghrelin may not efficiently cross the blood-brain barrier [72] , central targets of ghrelin action germane to energy homeostasis are located in regions of the hypothalamus and hindbrain that are not well protected by this barrier [31, 33] . The best documented of these targets are neurons in the hypothalamic arcuate nucleus that coexpress NPY and Agrp -both prototypic anabolic neuropeptides that promote positive energy balance [51] . Almost all arcuate NPY/Agrp neurons express the ghrelin receptor [73] , and ghrelin clearly activates these cells, as demonstrated by increases in their firing rate and their expression of c-fos (a marker of neuronal activity), Npy, and Agrp [4, 27, 30, [74] [75] [76] . Pharmacologic or genetic blockade of either NPY or Agrp signaling attenuates the orexigenic actions of ghrelin [4, 18, 77] , and genetic elimination of both genes ablates these actions [18] . Although hypothalamic NPY/Agrp neurons are unequivocal ghrelin targets, ghrelin may also exert orexigenic effects via indirect (vagally mediated) and direct signaling in the hindbrain [31, 78] . As a result of the fact that the hypothalamus and hindbrain are targets of ghrelin action and are key participants in energy homeostasis [51] , ghrelin clearly satisfies the second criterion for an adiposity signal.
Exogenous administration of an adiposity hormone should alter food intake and/or energy expenditure, and chronic infusions should change body weight
Peripheral or central ghrelin administration stimulates short-term food intake as potently as any known agent [30, 41] These agents often reduce food intake and body weight, although the specificity of this response needs to be confirmed using ghrelin receptor knockout mice. A novel type of ghrelin-blocking reagent, called ''RNA Spiegelmers'' (meaning ''RNA mirrors''), was recently described. These are oligonucleotides synthesized with unnatural L-enantiomers of ribose in the sugar-phosphate backbone, making them stable in vivo.
They have been designed to bind specifically and avidly to acylated ghrelin, thus preventing it from activating the ghrelin receptor in vitro and from stimulating GH in vivo [91 • ]. Tools such as these will allow investigators to determine definitively whether ghrelin is a key participant in energy homeostasis.
Support for the hypothesis that ghrelin is required to maintain normal body weight was recently provided by a classic hormone deletion/replacement study. Complete gastrectomy in mice, which reduced total and acylated ghrelin levels by 80%, caused reductions in body weight, fat mass, and lean mass. All these effects were reversed with exogenous ghrelin replacement, at a dose that restored only physiologic blood levels and did not affect body weight in sham-operated controls (Dickson S et al.
Paper presented at the fifth International Symposium on GH Secretagogues, Portofino-Vetta, Italy, 2004).
The reagents needed to determine whether ghrelin antagonism facilitates weight loss in humans are not yet available. Although some studies show linkage between polymorphisms in the human preproghrelin gene and protection against obesity and related sequelae [92] , the data are not definitive, and no cases have yet been reported of wasting from genetically defective ghrelin signaling. The phenotype of such mutations, however, is likely to be subtle, in view of the redundant pathways supporting body weight and the relatively minor impact of genetic elimination of ghrelin signaling in mice. Affected individuals might simply enjoy an unusual degree of leanness, and, considering themselves lucky, seek no medical attention for this. Existing population studies conducted to identify genes controlling body weight were designed to detect mutations that cause obesity; thus, mutations that do the opposite, as might occur with defective ghrelin signaling, are undetected.
Conclusion
Extant evidence favors roles for ghrelin in mealtime hunger and meal initiation, as well as in long-term body weight regulation. A critical question now is whether these roles are sufficiently vital that blockade of ghrelin signaling will durably promote weight loss in humans, despite compensatory adaptations from redundant heterologous systems that maintain body weight. Fortunately, excellent reagents to address this issue are rapidly being developed by pharmaceutical companies eager to market new antiobesity medications. Given that pharmacologic overstimulation of ghrelin signaling should theoretically be better able to override compensatory changes in other energy homeostatic pathways, ghrelin receptor agonists hold considerable promise to treat wasting conditions, for which few therapeutic options currently exist. The next few years should be exciting times for ghrelin research, as new tools become available to determine whether fascinating recent discoveries from the bench can be translated to the bedside.
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